Protéine CD20 pleine longueur exprimée HEK293 avec Nanodisc / DDM / VLP - ACROBiosystems
Anticorps monoclonal anti-CD20 (rituximab) dans les maladies hématologiques et les affections auto-immunes - ScienceDirect
CD20 Anticorps (FITC-65085) | Proteintech
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance | Oncogene
anti-CD20 (Rituximab) - ACE Biolabs Antibody │ Chemical │ Enzyme
Frontiers | Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
AntiCD20+ Agents - Practical Neurology
The future of anti-CD 20 monoclonal antibodies : are we making progress ? | Semantic Scholar
Brain Sciences | Free Full-Text | Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
Mechanisms of action of anti-CD20 monoclonal antibodies. Abbreviation:... | Download Scientific Diagram
Combining schematic of different effector mechanisms of anti CD20 mAbs... | Download Scientific Diagram
The applications of anti-CD20 antibodies to treat various B cells disorders - ScienceDirect
Characteristics of selected anti-CD20 monoclonal antibodies | Download Table
Establishment of C20Mab‑11, a novel anti‑CD20 monoclonal antibody, for the detection of B cells
Development of Anti-CD20 Antigen-Targeting Therapies for B-cell Lymphoproliferative Malignancies - The State of the Art | Bentham Science
Full article: Anti-CD20 treatment for B-cell malignancies: current status and future directions
Antibody drug development: Targeting CD20 and CD3
CD20 — Wikipédia
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance | Oncogene
Anti-mouse CD20 | 18B12-derived | InvivoGen
Anti-CD20 therapies for multiple sclerosis: current status and future perspectives | Journal of Neurology
Potential anti-CD20 mAb effector mechanisms. (A) Fc-Fc ␥ R–dependent... | Download Scientific Diagram
Noninvasive Evaluation of CD20 Expression Using 64Cu-Labeled F(ab′)2 Fragments of Obinutuzumab in Lymphoma | Journal of Nuclear Medicine
